Ubiali Alessandra, Cesar Conti Luiza, Dall'Ara Paola, De Maria Raffaella, Aresu Luca, Moretti Pierangelo, Sini Federica, Riondato Fulvio, Stefanello Damiano, Comazzi Stefano, Martini Valeria
Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi, Italy.
Department of Veterinary Sciences, University of Turin, Grugliasco, TO, Italy.
Front Vet Sci. 2024 Jul 26;11:1412227. doi: 10.3389/fvets.2024.1412227. eCollection 2024.
Programmed Death-Ligand 1 is a well-known immune checkpoint molecule. Recent studies evaluated its expression in different canine cancer types through different laboratory techniques. The present study aims to evaluate the surface membrane protein expression (mPD-L1) by means of flow cytometry (FC) in different canine lymphoma immunophenotypes. Furthermore, in a subset of cases, mRNA and plasmatic soluble protein (sPD-L1) have been assessed in the same patient, and correlations among results from the three analyses investigated.
Samples obtained for diagnostic purpose from untreated dogs with a confirmed lymphoma immunophenotype were included: surface protein was assessed via FC and quantified with median fluorescence index ratio (MFI ratio), gene expression was evaluated by real time quantitative polymerase chain reaction (RT-qPCR) and plasmatic concentration of soluble protein (sPD-L1) measured with ELISA. Statistical analyses were performed to investigate any difference among FC immunophenotypes, updated Kiel cytological classes, and in the presence of blood infiltration.
Considering FC, most B-cell lymphomas (BCL) were positive, with higher MFI ratios than other subtypes (81%, median MFI ratio among positive samples = 1.50, IQR 1.21-2.03, range 1.01-3.47). Aggressive T-cell lymphomas had a lower percentage of positive samples (56%) and showed low expression (median MFI ratio in positive samples = 1.14, IQR 1.07-1.32, range 1.02-2.19), while T-zone lymphomas (TZL) were frequently positive (80%) but with low expression (median MFI ratio in positive samples = 1.19, IQR 1.03-1.46, range 1.02-6.03). Cellular transcript and sPD-L1 were detected in all samples, without differences among immunophenotypes. No correlation between results from different techniques was detected, but sPD-L1 resulted significantly increased in FC-negative lymphomas ( = 0.023).
PD-L1 molecule is involved in canine lymphoma pathogenesis, with differences among immunophenotypes detected by FC. Specifically, BCL have the highest expression and aggressive T-cell lymphomas the lowest, whereas TZL need further investigations.
程序性死亡配体1是一种著名的免疫检查点分子。最近的研究通过不同的实验室技术评估了其在不同犬类癌症类型中的表达。本研究旨在通过流式细胞术(FC)评估不同犬淋巴瘤免疫表型中的表面膜蛋白表达(mPD-L1)。此外,在一部分病例中,对同一患者的mRNA和血浆可溶性蛋白(sPD-L1)进行了评估,并研究了三种分析结果之间的相关性。
纳入从确诊为淋巴瘤免疫表型的未经治疗的犬只获取的用于诊断目的的样本:通过FC评估表面蛋白并用中位荧光指数比(MFI比)进行定量,通过实时定量聚合酶链反应(RT-qPCR)评估基因表达,并用酶联免疫吸附测定(ELISA)测量血浆可溶性蛋白(sPD-L1)的浓度。进行统计分析以研究FC免疫表型、更新的基尔细胞学分类以及是否存在血液浸润之间的任何差异。
就FC而言,大多数B细胞淋巴瘤(BCL)呈阳性,其MFI比高于其他亚型(81%,阳性样本中的中位MFI比 = 1.50,四分位间距1.21 - 2.03,范围1.01 - 3.47)。侵袭性T细胞淋巴瘤的阳性样本百分比更低(56%)且表达较低(阳性样本中的中位MFI比 = 1.14,四分位间距1.07 - 1.32,范围1.02 - 2.19),而T细胞区淋巴瘤(TZL)经常呈阳性(80%)但表达较低(阳性样本中的中位MFI比 = 1.19,四分位间距1.03 - 1.46,范围1.02 - 6.03)。在所有样本中均检测到细胞转录本和sPD-L1,免疫表型之间无差异。未检测到不同技术结果之间的相关性,但sPD-L1在FC阴性的淋巴瘤中显著升高( = 0.023)。
PD-L1分子参与犬淋巴瘤的发病机制,FC检测到的免疫表型之间存在差异。具体而言,BCL表达最高,侵袭性T细胞淋巴瘤表达最低,而TZL需要进一步研究。